Jump to the top of the page

Investment Banking

The Quarterly Rx: Q3 2022 U.S. Biopharma Recap

While biopharma markets stabilized in Q3 2022—providing issuers with the most constructive financing environment we have seen year-to-date—macroeconomic issues remain the key headline risk for the near term. Key biopharma indices bounced off multiyear lows, driven by encouraging signs of M&A, meaningful positive clinical news, and broad sector short covering. William Blair's Biopharma team shares perspectives in “The Quarterly Rx: Q3 2022 U.S. Biopharma Recap.

Complete the form below to download your copy of the report.

Delivered to Your Inbox

Stay up-to-date with the latest William Blair news and insights

Subscribe to News Alerts

More News and Insights

  • Boyne Capital Partners Raises Single-Asset Continuation Fund for Pilot Energy

    William Blair acted as the exclusive financial advisor to Boyne Capital Partners in connection with the raising of its single-asset continuation fund to acquire Pilot Energy from BCM Fund I, LP and other shareholders.

    Read more

  • Why Companies Are Staying Private Longer — And What It Means for Investors

    William Blair’s Head of Private Shares Trading, Tony Frascotti, details the shift currently reshaping private markets.

    Read more

  • Xylem Inc.: Initiation of Research Coverage

    William Blair initiated research coverage of Xylem Inc. (XYL $142.91), the world’s largest pure-play water company.

    Read more
See more insights

Are you sure you want to leave?

Information contained on the internet is not subject to William Blair & Company's control or review, and may not be accurate.

For disclosure information, please visit www.williamblair.com/disclosures